Skye Bioscience Inc.

Today's conference call explored our fourth quarter and 2024 financial results in detail, along with an in-depth business update. From an accelerated timeline for and expansion of our CBeyond? Phase 2 obesity trial to highlights on research & development and manufacturing, we look forward to sharing more details on our upcoming milestones. To access today's call or other updated materials, please visit our website: https://lnkd.in/gZZBgQAS

Skye will host a conference call on March 20th to discuss our 2024 fourth-quarter and full-year financial results. After the market closes on March 20th, an earnings press release will also be issued. Please see today’s release for more details: https://lnkd.in/guVSSsdp

From panel discussions to interviews, meetings to networking, SXSW was an excellent opportunity to share the SKYE story and explore the landscape of the future of obesity treatment. We’ll be sharing more footage from the insightful 'Weighing in on Weight Loss Medicine’ panel featuring CEO Punit Dhillon and Advisory Board Member Dr. Beverly Tchang, MD, along with an interview between Punit and Dr. Tchang around different aspects of obesity treatment and how the topic has made it to such a large public venue as SXSW. Stay tuned for more coverage of Skye at SXSW.

Skye Chief Medical Officer Dr. Puneet Arora, MD, MS, FACE, presented a corporate overview at the TD Cowen 45th Annual Health Care Conference, exploring our mission, our lead molecule, the current obesity treatment landscape, and more. For the full recording, please visit our website: https://lnkd.in/gXbjkAb4

We’re only 4 days away from SXSW. For all those attending, we welcome you to join us on March 10th from 10am to 11am at the JW Marriott for the ‘Weighing in on Weight Loss Medicine' panel discussion. Featuring CEO Punit Dhillon and Advisory Board Member Dr. Beverly Tchang, MD, it will be an in-depth discussion on the future of weight loss, the potential impact of CB1, and more. Additional details on the panel can be viewed here: https://lnkd.in/e4hh6R_W?

This #WorldObesityDay, we stand with organizations around the globe to spotlight the systems that need to change to improve the health of our community. We look forward to sharing more about our progress, scientific advancements in the field, and information about obesity risk over the coming months.

Skye CEO Punit Dhillon recently contributed to Citeline's extensive Scrip Asks series, with Part 6 covering Therapeutic Area Advances. Speaking to the increased interest in CB1 inhibition and growing emphasis on patient-centric solutions, Punit’s expertise and experience in the field were shared alongside over 140 other biopharma leaders. Read the full article here: https://lnkd.in/g-3PysZ2

Today we announced that Skye will participate in this year's SXSW in Austin, Texas. Both CEO Punit Dhillon and Advisory Board Member Dr. Beverly Tchang, MD, will be panelists for 'Weighing in on Weight Loss Medicine', exploring the future of obesity management beyond GLP-1. We invite attendees to join us on March 10th from 10am to 11am CT at the JW Marriott and look forward to an in-depth discussion on new solutions and safer, more sustainable weight loss. Attracting over 300,000 participants annually from across the US and around the world, this global conference has long been a platform for thought leadership, scientific innovation, and cultural exploration. Read today’s full release here: https://lnkd.in/dmGJNn86

The Skye team will participate in the 45th Annual TD Cowen Health Care Conference, taking place in Boston on Wednesday, March 5th. Skye CEO Punit Dhillon will present a corporate overview to attendees, with a live webcast available through our website. We look forward to connecting with investors attending TD Cowen. 1x1 meetings can be requested through the conference 1x1 system. https://lnkd.in/gG-ZPwD6

On February 12th, Skye CEO Punit Dhillon gave a virtual corporate overview at Oppenheimer & Co. Inc.'s prestigious 35th Annual Healthcare Life Sciences Conference. It was an excellent opportunity to connect with the investment community and explore our pipeline, key corporate fundamentals, and our approach to improving the treatment of obesity. To access the recording, please visit our website: https://lnkd.in/gQVTwQt9